These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 6997101)

  • 21. Plasma insulin and C-peptide levels in cirrhotic and uremic patients.
    Kawai K; Hayakawa H; Yoshida K; Shimizu M; Noto Y
    Diabete Metab; 1977 Mar; 3(1):7-10. PubMed ID: 323089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucose kinetics and splanchnic uptake following mixed meal ingestion in cirrhotic-diabetic subjects.
    Kiwanuka E; Barazzoni R; Tessari P
    Diabetes Nutr Metab; 2001 Dec; 14(6):315-24. PubMed ID: 11853363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The glucoregulatory hormones in cirrhosis of the liver.
    Smith-Laing G
    Z Gastroenterol; 1979 Jul; 17(7):462-8. PubMed ID: 473836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of pancreatic and hepatic function in Yucatan miniature swine exhibiting impaired glucose tolerance.
    Spangler RS; Phillips RW
    Horm Metab Res; 1981 Dec; 13(12):669-72. PubMed ID: 7033093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minor physiological relevance of oral glucose tolerance test.
    Kühl C; Vandsted M; Olsen PG
    Diabete Metab; 1982 Sep; 8(3):203-7. PubMed ID: 6754492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism of the carbohydrate intolerance of cirrhosis.
    Proietto J; Alford FP; Dudley FJ
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1030-6. PubMed ID: 6999005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics.
    Tietge UJ; Böker KH; Manns MP; Bahr MJ
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E82-9. PubMed ID: 15010338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum lipids, insulin, and glucagon after portacaval shunt in cirrhosis.
    Shurberg JL; Resnick RH; Koff RS; Ros E; Baum RA; Pallotta JA
    Gastroenterology; 1977 Feb; 72(2):301-4. PubMed ID: 830579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone and carbohydrate intolerance in cirrhosis.
    Shankar TP; Solomon SS; Duckworth WC; Jerkins T; Iyer RS; Bobal MA
    Horm Metab Res; 1988 Sep; 20(9):579-83. PubMed ID: 3058569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diabetes mellitus secondary to liver diseases. A review (author's transl)].
    Guillon J; Charbonnel B
    Diabete Metab; 1975 Sep; 1(3):191-9. PubMed ID: 791727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon and insulin metabolism in cirrhotic patients.
    Yoshida T; Ninomiya K; Matsumoto T; Baatar D; Bandoh T; Kitano S
    Hepatogastroenterology; 1998; 45(20):468-71. PubMed ID: 9638429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin.
    Hamberg O
    Dan Med Bull; 1997 Jun; 44(3):225-41. PubMed ID: 9233544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal.
    Marchesini G; Melli A; Checchia GA; Mattioli L; Capelli M; Cassarani S; Zoli M; Pisi E
    Metabolism; 1985 Aug; 34(8):695-701. PubMed ID: 3894876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose resistance contributes to diabetes mellitus in cirrhosis.
    Petrides AS; Schulze-Berge D; Vogt C; Matthews DE; Strohmeyer G
    Hepatology; 1993 Aug; 18(2):284-91. PubMed ID: 8340056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Portal systemic shunting of insulin does not lead to insulin resistance in patients with extrahepatic portal vein obstruction.
    Modi GK; Shah P; Acharya SK; Guleria R
    Horm Metab Res; 1999 Aug; 31(8):462-6. PubMed ID: 10494871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.
    Johnson KM; Edgerton DS; Rodewald T; Scott M; Farmer B; Neal D; Cherrington AD
    Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1085-91. PubMed ID: 17684104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Portal vein blood insulin and glucagon are increased in experimental hyperthyroidism.
    Wolf E; Eisenstein AB
    Endocrinology; 1981 Jun; 108(6):2109-13. PubMed ID: 7014195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: relationship to hypertension.
    Iannello S; Campione R; Belfiore F
    Mol Genet Metab; 1998 Mar; 63(3):214-23. PubMed ID: 9608544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose, insulin and somatostatin infusion for the determination of insulin resistance in liver cirrhosis.
    Greco AV; Rebuzzi AG; Altomonte L; Manna R; Bertoli A; Ghirlanda G
    Horm Metab Res; 1979 Oct; 11(10):547-9. PubMed ID: 521009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.